CAS: 3055-98-9; 3,6,9,12,15,18,21,24-Octaoxahexatriacontan-1-Ol

相似化合物

3055-99-0 19327-39-0 5274-63-5

上下游产品

CAS号112-60-7 三缩四乙二醇 | CAS号81782-65-2 1-(2-{2-[2-(2-c...

📜1,3,6,9,12-Pentaoxa-2-Thiacyclotetradecane 2,2-Dioxide置于sodium Hydride体系中,用 四氢呋喃,Mineral Oil 作为反应溶剂,化学反应 5.0H,反应生成 辛乙烯二醇单正十二烷基酯
参考文献:Application Of Monodisperse Pegs In Pharmaceutics: Monodisperse Polidocanols
标题:Application Of Monodisperse Pegs In Pharmaceutics: Monodisperse Polidocanols
摘要:Polydisperse Pegs Are Ubiquitously Used In Pharmaceutical Industry And Biomedical Research. However,The Monodispersity In Pegs May Play A Role In The Development Of Safe And Effective Pegylated Small Molecular Drugs. Here,To Avoid The Polydispersity In Polidocanol,The Active Ingredient In A Clinically Used Drug,A Macro Cyclic Sulfate-Based Strategy For The Efficient And Scalable Synthesis Of Monodisperse Polidocanols,Their Sulfates,And Their Methylated Derivatives,Was Developed. Tlc And HPLC Analysis Indicated A Complex Mixture In Regular Polidocanol And High Purifies In Monodisperse Polidocanols And Their Derivatives. Assay On Huvec,L929,And Hepg2. Cells Showed-That Monodisperse Polidocanols Have Much Higher Cytotoxicity And Safety Than That Of Regular Polidocanol. It Was Found That The Monodispersity Of Pegs In Polidocanols Is Crucial For Achieving The Optimal Therapeutic Results. Therefore,Based On This Case Study,It Would Be Beneficial To Optimize Pegylated Small Molecular Drugs With Monodisperse Pegs In Pharmaceutical Research And Development.
DOI:10.1021/acs.Molpharmaceut.7B00496

专利信息

专利号:US-2012190064-A1
优先权日:2004-10-01
标题 :Feeding buffers, systems, and methods for in vitro synthesis of biomolecules
发明人：KUDLICKI WIESLAW ANTONI; KEPPETIPOLA SHIRANTHI; FLETCHER JULIA; GETBEHEAD ASHLEY ELAINE; KATZEN FEDERICO; VOZZA-BROWN LAURA
权利人:KUDLICKI WIESLAW ANTONI; KEPPETIPOLA SHIRANTHI; FLETCHER JULIA; GETBEHEAD ASHLEY ELAINE; KATZEN FEDERICO; VOZZA-BROWN LAURA; LIFE TECHNOLOGIES CORP
摘要:Compositions, methods and kits for in vitro systems for synthesis of biomolecules such as polypeptides, are provided herein. Cell extracts that provide enhanced yields of soluble proteins using in vitro protein synthesis methods are provided. The invention also includes methods for producing high yields of proteins by the addition of a feeding solution that includes amino acids and an energy source to an ongoing in vitro synthesis system. The invention also includes methods of using a high-yield in vitro synthesis system to produce large quantities of proteins with incorporated labeled amino acids for analysis by methods such as by NMR. The invention further includes vectors for enhanced production of proteins from nucleic acid templates using in vitro synthesis systems.

专利号:US-6217901-B1
优先权日:1999-05-25
标题:Liposome-assisted synthesis of polymeric nanoparticles
发明人：PERROTT MICHAEL G; BARRY STEPHEN E
权利人:ALNIS LLC
摘要:Synthetic polymer complements (SPCs) are provided, as well as methods for their synthesis and use. The SPCs range in size from about 20 to about 1000 nm. The SPCs have surfaces that are complementary to surface sites of target molecules, resulting in the ability of the SPCs to selectively bind to molecular targets. The molecular recognition capability of these particles enables their use in diagnostic, therapeutic, and separation applications. The SPC is formed by contacting a target template molecule with a set of building blocks solubilized in the interior of a liposome, which building blocks are then polymerized into a network to form the synthetic polymer complement in the interior of the liposome. The target templates are removed to produce complementary sites in a SPC that map the surface of the target, resulting in a water-soluble SPC nanoparticle of similar dimensions as the interior of the liposome that originally supported it and capable of molecular recognition.

专利号:WO-2025088147-A1
优先权日:2023-10-27
标题 :Theranostic psma-targeting ligands for the diagnosis and treatment of psma-expressing cancers and their solid phase synthesis
发明人：Schäfer Martin; BAUDER-WUEST ULRIKE; ROSCHER MAREIKE; REMDE YVONNE; BENEÅ OVÃ?-SCHÄFER MARTINA; BARINKA CYRIL; KUTILOVÃ? ZSÓFIA; MOTLOVÃ? LUCIA
权利人:DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS
摘要:The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and radiopharmaceuticals for the treatment of various disease states of PSMA-expressing cancers, especially prostate cancer, and metastases thereof. Further the present invention provides synthetic procedures for the synthesis of such PSMA-targeting ligands.

专利号:WO-2024130393-A1
优先权日:2022-12-21
标 题 :Nanoparticle and method of synthesis thereof
发明人：MOSKOVCHENKO SVITLANA
权利人:MOSKOVCHENKO SVITLANA
摘要:The present technology relates to nanoparticles, compositions comprising said nanoparticles, and methods of synthesis of said nanoparticles; wherein the nanoparticles comprise a metal nanoparticle core, a first coating of amphiphilic molecules, and a second coating of essential oil, essential oil primary constituent, or both, which combine the antimicrobial properties of metal nanoparticles, amphiphilic molecules, and essential oil or essential oil primary constituents.

专利号:US-2024010511-A1
优先权日:2019-05-02
标 题 :Methods and compositions for synthesis of phosphor and its incorporation in a polymer matrix for light conversion
发明人：SAHI SUNIL
权利人:SOLGO INC; SOLGRO INC
摘要:The invention relates to methods and compositions for synthesizing a phosphor and preparing a surface-modified phosphor comprising a phosphor, a silica, and a silane, and articles comprising same. The invention also relates to a method of dispersion of the disclosed surface-modified phosphor with a blue emitting agent in a polymer matrix and uses thereof.

专利号:US-2017190670-A1
优先权日:2014-07-11
标题:Improved process for the preparation of enzalutamide
发明人：HIRPARA SANJAY; SHRAWAT VIMAL KUMAR; POTHURAJU RAJU; TRIPATHI CHANDRESH KUMAR; AKSHAYKANT CHATURVEDI
权利人:SHILPA MEDICARE LTD
摘要:The present application relates to an improved process for preparation of Enzalutamide (I). n n n n n n n n n n The present application also relates to an improved process for the preparation of substantially pure Enzalutamide (I) having purity of greater than 99.5%. n The present application also relates to a novel process for the preparation of Enzalutamide intermediate useful in the industrially viable synthesis of Enzalutamide.